İsMail Dilli

İsMail Dilli

Auto-generated profile, based on publicly available information

İsMail Dilli

Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2025 in Anatolian Current Medical Journal
Verified
Journal Article
Open access
PDF file
SKSalih Karatlı
Salih Karatlı
IDİsMail Dilli
İsMail Dilli
MAMustafa Altınbaş
Mustafa Altınbaş
Aims: The CALLY index, integrating C-reactive protein (CRP), albumin, and lymphocyte count, has been identified as a promising prognostic biomarker in various cancers. The present study aims to evaluate its prognostic significance in De Novo metastatic colorectal cancer (mCRC). Methods: A retrospective analysis was conducted on 108 patients diagnosed with de novo mCRC at Ankara Etlik City Hospital (2021–2024). The CALLY index was calculated from baseline laboratory values and dichotomized at the median (0.2018). Progression-free survival (PFS) and overall survival (OS) were compared between low and high CALLY groups using the Kaplan–Meier method and log-rank test. The associations between the CALLY index and tumour location, as well as RAS/BRAF mutation status, were evaluated using the chi-square test. Cox regression analyses were also performed to determine independent prognostic factors. Results: Patients with elevated CALLY scores exhibited significantly prolonged median PFS (24.0 vs. 13.0 months; p

15 December 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
EZEsra Zeynelgil
Esra Zeynelgil
EKEngin Eren Kavak
Engin Eren Kavak
IDİsMail Dilli
İsMail Dilli
ÖİÖzlem Aydın İsak
Özlem Aydın İsak
DYDoğan Yazılıtaş
Doğan Yazılıtaş
ÖBÖmer Bayır
Ömer Bayır
This study aimed to evaluate the clinical and laboratory factors affecting treatment response and treatment tolerance in patients diagnosed with head and n

1 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EKEngin Eren Kavak
Engin Eren Kavak
EEEfe Cem Erdat
Efe Cem Erdat
ZDZeynep Altundağ Derin
Zeynep Altundağ Derin
IDİsMail Dilli
İsMail Dilli
PTPınar Kubilay Tolunay
Pınar Kubilay Tolunay
HAHakan Akbulut
Hakan Akbulut
This study compares survival predictions made by an artificial intelligence (AI) based chatbot with real-world data in hepatocellular carcinoma (HCC) patients. It aims to evaluate the reliability and accuracy of AI technologies in HCC prognosis. A retrospective analysis was conducted on patients diagnosed with HCC. The estimated survival times for each patient were calculated using an artificial intelligence chatbot. The follow-up periods and mortality data for the patients were used to obtain real-life survival data. The predicted and actual survival times were statistically compared. ChatGPT-4o consistently overestimated the overall survival (OS) times compared to real-world outcomes.A statistically significant discrepancy was observed between the predicted and actual survival times (p < 0.05). Nevertheless, while the survival predictions of AI were more accurate in patients with advanced-stage HCC, the predictions differed significantly in patients with early-stage HCC. AI has the potential to play an important role in the prognosis of complex diseases such as HCC. However, this study’s findings indicate that AI’s predictions are not entirely consistent with real-world data, particularly in the context of early-stage diseases. Further large-scale studies may enhance the dependability of incorporating AI into clinical decision-support systems. The use of AI-assisted predictions may prove to be a valuable tool for the prediction of survival in patients with HCC. Nevertheless, further studies are required to substantiate the accuracy and reliability of these systems before they can be implemented in clinical practice.

24 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SÇselahattin çelik
selahattin çelik
EKEngin Eren Kavak
Engin Eren Kavak
EZEsra Zeynelgil
Esra Zeynelgil
GİGökşen İnanç İmamoğlu
Gökşen İnanç İmamoğlu
IDİsmail Dilli
İsmail Dilli
TETülay Eren
Tülay Eren
Background: Immune checkpoint inhibitors (ICIs) targeting the PD-1 axis represent standard second-line therapy for metastatic non-small cell lung cancer (NSCLC). Emerging data suggest that SARS-CoV-2 mRNA vaccines may enhance antitumor immunity through innate immune activation and type I interferon signaling, potentially sensitizing tumors to PD-1 blockade. The clinical impact of patients initiating second-line nivolumab remains unclear. Methods: In this retrospective single-center cohort study, 88 patients with recurrent stage IV NSCLC who received second-line nivolumab between 1 January 2023 and 1 January 2026 were analyzed. Vaccination exposure was defined using a 6-month pre-treatment window prior to nivolumab initiation (T0). Patients were stratified according to receipt of ≥2 versus 0–1 mRNA COVID-19 vaccine doses within the 6 months preceding T0 (n = 45 and n = 43, respectively). The primary endpoint was progression-free survival from nivolumab initiation (PFS2). Survival outcomes were estimated using the Kaplan–Meier method and evaluated using Cox regression models. Results: With a median follow-up of 22.4 months, median PFS2 for the overall cohort was 11.1 months (95% CI, 9.4–15.1). Patients receiving ≥2 mRNA doses had significantly longer PFS2 than those receiving 0–1 dose (14.0 vs. 9.6 months; p = 0.04). In multivariable analysis, ≥2 doses were independently associated with reduced risk of progression or death (aHR 0.52, 95% CI 0.31–0.88; p = 0.01). Non-adenocarcinoma histology and baseline brain metastasis were independently associated with shorter PFS2. Conclusions: Receipt of ≥2 mRNA vaccine doses within 6 months before nivolumab initiation was independently associated with prolonged PFS2 in metastatic NSCLC. Prospective multicenter validation is warranted.

16 September 2025 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
EKEngin Eren Kavak
Engin Eren Kavak
IDİsMail Dilli
İsMail Dilli
ÖBÖmer Bayır
Ömer Bayır
HDHüseyin Demirci
Hüseyin Demirci
SÖSamet Özlügedik
Samet Özlügedik
Aims: This study aimed to evaluate the prognostic value of the Systemic Immune-Inflammation Index (SII) in patients with head and neck cancer and its association with survival outcomes including disease-free survival (DFS) and overall survival (OS). Methods: The patients diagnosed with head and neck cancer were retrospectively analyzed. Patients were stratified into two groups based on the SII cut-off value (796): low SII (L-SII) and high SII (H-SII). Clinical, demographic, and treatment-related parameters were compared between the groups. Kaplan-Meier survival analysis and Cox regression were used for univariate and multivariate analyses of DFS and OS. Results: Of the total number of patients included in the study (n=184), 67 with high SII (≥796) exhibited significantly higher recurrence rates (43.3% vs. 8.5%, p

13 January 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
TETülay Eren
Tülay Eren
EKEngin Eren Kavak
Engin Eren Kavak
IDİsmail Dilli
İsmail Dilli
EZEsra Zeynelgil
Esra Zeynelgil
Objective: The aim of this study was to assess the association between the Lung Immune Prognostic Index (LIPI) measured at diagnosis and both event-free survival (EFS) and overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC). Methods: This retrospective cohort included patients diagnosed with stage III NSCLC between September 2022 and July 2024, all of whom had a minimum follow-up duration of six months. LIPI was calculated using the derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase levels at diagnosis. Clinical, demographic, and treatment-related data were systematically collected. Survival outcomes were estimated using the Kaplan–Meier approach, while factors associated with prognosis were examined through Cox proportional hazards models. Results: The study population consisted of 68 patients, predominantly male (86.8%), with a mean age of 63.4 ± 8.7 years. According to the Lung Immune Prognostic Index classification, 29 patients (42.6%) were categorized as having a good score, 27 (39.7%) as intermediate, and 12 (17.6%) as poor. During a median follow-up of 15.4 months, a total of 40 progressions and 22 deaths occurred. Median EFS was 17.7, 9.4, and 5.8 months for good, intermediate, and poor LIPI groups, respectively (p < 0.001). Median OS was 25.7 months in the good LIPI group, was not reached in the intermediate group due to insufficient events, and was 6.7 months in the poor group (p < 0.001). In multivariate Cox analysis, poor LIPI was independently associated with inferior survival (EFS: HR = 2.87, 95% CI: 1.85–4.46, p < 0.001; OS: HR = 2.59, 95% CI: 1.40–4.78, p = 0.002). Conclusions: LIPI calculated at diagnosis is an independent prognostic factor for both EFS and OS in stage III NSCLC. Validation in larger, prospective cohorts is warranted to further define its prognostic role in stage III NSCLC.